IBI-A-4a Response Accepted in Part

Interferon Treatment Impacts

Recommendation

People infected with Hepatitis B or C who have received a course of treatment with or based on interferon should be recognised as entitled to core awards at Level 3.

Published Evidence Summary
The following publicly available evidence relates to this recommendation:
The government accepted in principle the recommendation to recognise the impact of interferon treatment, suggesting either moving affected individuals to a Level 3 equivalent or introducing a new infection severity band (Official government response, 21 July 2025). The Infected Blood Compensation Authority (IBCA) has made offers totalling £2.47 billion, with £1.89 billion paid to 2,861 people by January 2026, and the third set of compensation regulations came into force on 31 December 2025 (IBCA Community Update, 15 Jan 2026; IBCA Independent Review, 28 Oct 2025). However, specific details on how the interferon treatment impact has been incorporated into these regulations are not explicitly detailed in the available evidence.
How was this assessed?
Assessed by gemini-2.5-flash on 24 Mar 2026
Checked data held on this site (government responses, progress updates, independent evidence)
External sources searched: www.gov.uk, www.legislation.gov.uk, hansard.parliament.uk
Jurisdiction
UK-wide
Response
Accepted in Part
Accepted in Part UK Government
21 Jul 2025

The impact of interferon treatment on those infected with Hepatitis B or C often resulted in severe side effects, both psychological and physical. The Inquiry recommended that more be done to recognise the impact of interferon in the scheme. The Inquiry proposed that interferon could be better recognised by moving all those who received it to the equivalent of Cirrhosis Level 3 band. Alternatively the Inquiry suggested the Government could introduce a new infection severity band, between Level 2 (Chronic) and Level 3 (Cirrhosis). The Government proposes to introduce a new core route infection severity band for those who received interferon treatment, to be referred to as Level 2B. The Government will consult on the proposed awards for Level 2B to ensure these properly reflect the impacts of interferon treatment.

Read Full Response
Published Evidence

Published assessments of implementation progress from inspectorates, select committees, official progress reports, and other sources. Check the source type badge to see whether each assessment is independent or government self-reported.

Good Progress
15 Jan 2026
IBCA Community Update Other

As of 13 January 2026: 3,721 people asked to start claims, 3,546 begun process, 3,074 received offers totalling £2.47bn, 2,861 paid totalling £1.89bn. Third compensation regulations in force 31 December 2025.

View detailed findings

IBCA exceeded initial expectations. Three sets of regulations now in force covering infected persons, affected persons, and supplementary routes. £11.8bn committed in October 2024 Budget. Independent review found "very creditable progress."

IBCA Community Update, 15 January 2026 View Source
Reasonable Progress
28 Oct 2025
IBCA Independent Review Other

IBCA has contacted 2,215 people to begin compensation claims; 1,934 started process. £812m+ paid via Horizon Shortfall Scheme. £11.8bn committed in Autumn Budget.

View detailed findings

IBCA exceeded expectations for first cohort and established operational service with "compassionate ethos." Target: bulk of infected payments by 2027, affected by 2029. Third compensation scheme regulations came into law 31 December 2025.

IBCA CO-Sponsored Independent Review Report, Octo… View Source
Source
Report Additional Report on Compensation 09 Jul 2025
Responsible Bodies
UK Government Primary
Recommendation age 0.7 yr
Last formal update 21 Jul 2025